Univariate and multivariate Cox regression analysis of risk factors for time to progression
| Risk factor . | Univariate analysis . | P . | Multivariate analysis . | P . | ||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | HR . | 95% CI . | |||
| Stage III disease | 1.9 | 1.2-2.8 | .004 | — | — | NS |
| Hb level less than or equal to 6.21 mM | 1.9 | 1.4-2.7 | < .001 | 2.0 | 1.4-3.0 | < .001 |
| Calcium greater than 2.65 mM | 1.7 | 1.1-2.6 | .02 | — | — | NS |
| β2-microglobulin greater than 3 mg/L | 1.6 | 1.1-2.3 | .02 | — | — | NS |
| LDH greater than ULN | 2.1 | 1.3-3.2 | .002 | 2.2 | 1.3-3.5 | .002 |
| Plasma cells LI greater than 1% | 2.7 | 1.3-5.6 | .008 | — | — | NI |
| β2-microglobulin greater than 3 mg/L after VAD | 1.9 | 1.2-3.1 | .006 | — | — | NI |
| Skeletal lesions (0 vs 1-2 vs 3 or more) | 1.3 | 1.0-1.6 | .03 | — | — | NS |
| Response on VAD | 0.9 | 0.6-1.3 | .48 | — | — | NI |
| Myeloablative treatment | 0.7 | 0.5-1.0 | .04 | — | — | NS |
| Risk factor . | Univariate analysis . | P . | Multivariate analysis . | P . | ||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | HR . | 95% CI . | |||
| Stage III disease | 1.9 | 1.2-2.8 | .004 | — | — | NS |
| Hb level less than or equal to 6.21 mM | 1.9 | 1.4-2.7 | < .001 | 2.0 | 1.4-3.0 | < .001 |
| Calcium greater than 2.65 mM | 1.7 | 1.1-2.6 | .02 | — | — | NS |
| β2-microglobulin greater than 3 mg/L | 1.6 | 1.1-2.3 | .02 | — | — | NS |
| LDH greater than ULN | 2.1 | 1.3-3.2 | .002 | 2.2 | 1.3-3.5 | .002 |
| Plasma cells LI greater than 1% | 2.7 | 1.3-5.6 | .008 | — | — | NI |
| β2-microglobulin greater than 3 mg/L after VAD | 1.9 | 1.2-3.1 | .006 | — | — | NI |
| Skeletal lesions (0 vs 1-2 vs 3 or more) | 1.3 | 1.0-1.6 | .03 | — | — | NS |
| Response on VAD | 0.9 | 0.6-1.3 | .48 | — | — | NI |
| Myeloablative treatment | 0.7 | 0.5-1.0 | .04 | — | — | NS |
HR indicates hazard ratio; —, not applicable; NS, not significant; Hb, hemoglobin; NI, not included in multivariate analysis.